Rheumatoid Arthritis Treatment Market
Rheumatoid Arthritis Treatment Market Study by Symptomatic Treatment, Intermediate Corticosteroid Therapy, Stem Cell Therapy, Disease Modifying and Anti-rheumatic Drugs from 2024 to 2034
Analysis of Rheumatoid Arthritis Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Rheumatoid Arthritis Treatment Market Outlook (2024 to 2034)
The global rheumatoid arthritis treatment market size is evaluated at US$ 35.84 billion in 2024. According to projections by Fact.MR in its latest market study, worldwide sales of rheumatoid arthritis treatment are forecasted to increase at a CAGR of 6% to reach US$ 64.17 billion by 2034-end.
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the joints and causes swelling and discomfort. In rheumatoid arthritis, the immune system of the body targets its own tissues, including the joints. One painful side effect of rheumatoid arthritis is the swelling of joint linings. It impacts approximately 1.3 million individuals in the United States and is becoming more common worldwide.
Key Market Growth Drivers
- Increasing incidence of rheumatoid arthritis worldwide is a major driver for the rheumatoid arthritis treatment market growth. There is an increasing need for effective treatment options due to the rising cases of chronic autoimmune diseases.
- Ongoing research in pharmacology and biotechnology is also fueling the development of new drugs with enhanced safety and efficacy.
- Biologics and targeted therapies are becoming more and more important in the treatment of rheumatoid arthritis.
- Aging populations are more likely to experience rheumatoid arthritis, which is projected to fuel the need for more rheumatoid arthritis medications.
- More people are seeking medical attention for rheumatoid arthritis as a result of increased awareness of the condition and the value of early diagnosis and treatment. Rheumatoid arthritis research and development are supported by government initiatives and policies.
- Pollution, chemical exposure, and dietary choices can all affect the immune system, making people more susceptible to autoimmune diseases such as rheumatoid arthritis. An increase in seropositive rheumatoid arthritis treatment is also contributing to market growth.
- Changing eating habits, such as consumption of processed foods high in sugar and unhealthy fats, is also causing inflammation and immunological dysregulation, which raises the prevalence of rheumatoid arthritis.
| Report Attributes | Details |
|---|---|
| Rheumatoid Arthritis Treatment Market Size (2024E) | US$ 35.84 Billion |
| Forecasted Market Value (2034F) | US$ 64.17 Billion |
| Global Market Growth Rate (2024 to 2034) | 6% CAGR |
| Latin America Market Growth Rate (2024E) | 4.5% CAGR |
| North America Market Share (2024E) | 43.4% |
| Market Value of Hospitals Segment (2024E) | US$ 30.16 Billion |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What are the Opportunities for Rheumatoid Arthritis Treatment Providers?
“Growing Awareness about Symptoms and Remittance Treatments for Rheumatoid Arthritis”
Rising healthcare costs, especially in developed nations, and increasing awareness about symptoms and remittance treatments for rheumatoid arthritis are projected to fuel sales of associated drugs. Higher prevalence rates, the introduction of new therapeutic agents, and the increase in the elderly population susceptible to rheumatoid arthritis are major rheumatoid arthritis treatment market trends.
- According to the Arthritis Foundation, about 65% of Americans between the ages of 60 and 65 are expected to be affected by an arthritis-related illness.
What are the Hindrances to Rheumatoid Arthritis Treatment Market Growth?
“Lack of Insurance Coverage in Developing Nations and Availability of Biosimilar Substitutes”
Main obstacles faced by providers of rheumatoid arthritis drugs and therapeutics are the lack of insurance coverage for certain medications in developing nations, the patent expiration of some drugs, and the unavailability of treatment.
It is challenging for drug manufacturers to establish an adequate market share and make sufficient revenue to meet the significant expenses of research and development that come with developing biologics. The availability of biosimilar substitutes is also contributing to the affordability problem because, despite efforts to reduce prices through competition, they frequently result in only slight price reductions.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
North America occupies 43.4% of the global rheumatoid arthritis treatment market share in 2024. Market expansion in this region is being driven by increased public and private spending on healthcare, a growing incidence of RA, and rising patient awareness of disease remittance therapies. Market growth is also supported by the swift approval of innovative medications, a robust clinical pipeline, easy access to high-quality healthcare, and advantageous reimbursement policies.
What’s Pushing Rheumatoid Arthritis Treatment Market Size in the United States?
“Growing Pool of Patients with Rheumatoid Arthritis”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 14.11 Billion |
| Growth Rate (2024 to 2034) | 5.5% CAGR |
| Projected Value (2034F) | US$ 24.19 Billion |
The United States accounts for 90.8% share of the North American market in 2024.
- According to the Centers for Disease Control and Prevention, 58.5 million Americans, or about one in four, suffer from arthritis.
- According to the National Library of Science, an estimated 1.3 million adults suffer from RA, accounting for 0.6% to 1% of the total adult population in the United States. About 35% of people with RA reported having a work disability related to their condition. In the United States, for patients of rheumatoid arthritis, the estimated annual total cost of healthcare is US$ 19.3 billion.
How is the Healthcare Sector in Brazil Contributing to Market Growth?
“Widespread Acceptance of Generic Arthritis Medications”
| Attribute | Brazil |
|---|---|
| Market Value (2024E) | US$ 1.14 Billion |
| Growth Rate (2024 to 2034) | 6.3% CAGR |
| Projected Value (2034F) | US$ 2.1 Billion |
Demand for rheumatoid arthritis treatment in Brazil is projected to reach a value of US$ 2.1 billion by the end of 2034. Brazil occupies 71.5% share of the Latin American market in 2024. Due to their lower cost, generic medications for arthritis are more widely accepted in price-sensitive countries such as Brazil. The market is projected to benefit from an increase in demand for new approaches to disease reversal.
Category-wise Insights
Demand for rheumatoid arthritis medications worldwide is divided into categories such as uric acid drugs, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and others based on drug class. It is divided into over-the-counter and prescription medications based on sales channel.
Depending on the sales channel, the prescription-based drug segment accounts for a significant share of the global market due to benefits such as patients receiving the correct dosage of the drug during rheumatoid arthritis treatment, without causing any side effects, and reducing the potential scope of drug misuse.
How are DMARDs Effective in the Treatment of Rheumatoid Arthritis?
“Effectiveness of DMARDs in Slowing Down Joint Damage Progression Driving Sales”
| Attribute | DMARDs |
|---|---|
| Segment Value (2024E) | US$ 32.17 Billion |
| Growth Rate (2024 to 2034) | 6% CAGR |
| Projected Value (2034F) | US$ 57.75 Billion |
DMARDs, which are extensively used in the treatment of rheumatoid arthritis, account for a 90% market share in 2024. DMARDs are used as the first-line treatment for rheumatoid arthritis, as they are known for their effectiveness in managing associated symptoms such as joint pain, stiffness, and inflammation. They help slow down or halt joint damage progression.
DMARD medications should typically be started as soon as a rheumatoid arthritis diagnosis is confirmed. DMARDs are used in combination with NSAIDs for better patient outcomes. The wide spectrum of drugs that DMARDs encompass allows for personalized treatments.
Why Do Hospital Pharmacies Account for High Sales of Rheumatoid Arthritis Drugs?
“Hospital Pharmacies Offer Easy Access to Necessary Medications and Related Services”
| Attribute | Hospitals |
|---|---|
| Segment Value (2024E) | US$ 30.16 Billion |
| Growth Rate (2024 to 2034) | 6% CAGR |
| Projected Value (2034F) | US$ 54.21 Billion |
In terms of distribution channel, the rheumatoid arthritis treatment market is broken down into hospital pharmacies, retail pharmacies, and drugstores. Hospital pharmacies account for an 84.2% market share in 2024. Hospitals help patients with standardized and personalized pharmaceutical services to meet their prescription counseling needs while also increasing adherence and therapeutic effectiveness.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Key players in the rheumatoid arthritis treatment market are Boehringer Ingelheim GmbH, AbbVie, Regeneron Pharmaceuticals, Inc., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., UCB S.A., F. Hoffmann-La Roche Ltd., Amgen, Inc., Johnson & Johnson Services Inc, Merck & Co. Inc., Bristol-Myers Squibb Company and Eli Lilly and Company.
- According to research, rheumatoid arthritis affects half a million people in the United Kingdom. It further states that the disease most commonly begins in middle age, but much younger age groups are afflicted, and until now there is no cure or prevention. The study published in The Lancet by a team led by King's College London involving Birmingham University researchers offers hope to arthritis patients by demonstrating that the biologic drug abatacept slows the progression of this agonizing chronic inflammatory disease.
- In October 2023, a team of scientists led by KOO Sagang from Seoul National University and the Center for Nanoparticle Research within the Institute for Basic Science Center (IBS) collaborated with researchers from the Korea Institute of Science and Technology (KIST) and Seoul National University to develop a new treatment for rheumatoid arthritis (RA).
- The new platform involves immobilizing ceria nanoparticles (Ce NPs) on mesenchymal stem cell-derived nanovesicles (MSCNVs). Both of these components can inhibit various pathogenic factors, allowing them to work independently and collaboratively to achieve a comprehensive treatment.
Segmentation of Rheumatoid Arthritis Treatment Market Research
-
By Therapy :
- Symptomatic Treatment
- Intermediate Corticosteroid Therapy
- Stem Cell Therapy
- Disease Modifying Anti-rheumatic Drugs (DMARDs)
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Drugstores
-
By Region :
- North America
- Europe
- Latin America
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions/Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Therapy modifications /Innovation 4. Key Success Factors 4.1. Strategic Developments 4.2. Key regulations 4.3. Therapy USPs /Technology 4.4. List of Manufacturers and Providers 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Outlook 5.1.2. Increasing R&D Expenditure 5.2. Forecast Factors - Relevance & Impact 5.2.1. New Therapy launches 5.2.2. Cost of Therapys 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Volume (Units) Analysis 2018 to 2023 and Forecast, 2024 to 2034 6.1. Historical Market Volume (Units) Analysis, 2018 to 2023 6.2. Current and Future Market Volume (Units) Projections, 2024 to 2034 6.2.1. Y-o-Y Growth Trend Analysis 7. Global Market - Pricing Analysis 7.1. Regional Pricing Analysis By Therapy 7.2. Pricing Break-up 7.2.1. Manufacturer Level Pricing 7.2.2. Distributor Level Pricing 7.3. Global Average Pricing Analysis Benchmark 8. Global Market Value Analysis 2018 to 2023 and Forecast, 2024 to 2034 8.1. Historical Market Value (US$ Mn) Analysis, 2018 to 2023 8.2. Current and Future Market Value (US$ Mn) Projections, 2024 to 2034 8.2.1. Y-o-Y Growth Trend Analysis 8.2.2. Absolute $ Opportunity Analysis 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Therapy 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Therapy, 2018 to 2023 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapy, 2024 to 2034 9.3.1. Symptomatic Treatment 9.3.2. Intermediate Corticosteroid Therapy 9.3.3. Stem Cell Therapy 9.3.4. Disease Modifying Anti-rheumatic Drugs (DMARDs) 9.4. Market Attractiveness Analysis By Therapy 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2018 to 2023 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024 to 2034 10.3.1. Hospital Pharmacies 10.3.2. Retail Pharmacies 10.3.3. Drugstores 10.4. Market Attractiveness Analysis By Distribution Channel 11. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Region 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2018 to 2023 11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2024 to 2034 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 12.3.1. By Country 12.3.1.1. U.S. 12.3.1.2. Canada 12.3.2. By Therapy 12.3.3. By Distribution Channel 12.4. Market Attractiveness Analysis 12.5. Key Market Participants - Intensity Mapping 12.6. Drivers and Restraints - Impact Analysis 13. Latin America Market Analysis 2018 to 2023 and Forecast 2024 to 2034 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Therapy 13.3.3. By Distribution Channel 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. U.K. 14.3.1.5. Spain 14.3.1.6. Russia 14.3.1.7. Rest of Europe 14.3.2. By Therapy 14.3.3. By Distribution Channel 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. South Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Thailand 15.3.1.3. Indonesia 15.3.1.4. Malaysia 15.3.1.5. Rest of South Asia 15.3.2. By Therapy 15.3.3. By Distribution Channel 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. East Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.1.4. Rest of East Asia 16.3.2. By Therapy 16.3.3. By Distribution Channel 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. Oceania Market Analysis 2018 to 2023 and Forecast 2024 to 2034 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Therapy 17.3.3. By Distribution Channel 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 to 2023 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024 to 2034 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. South Africa 18.3.1.3. Rest of Middle East and Africa 18.3.2. By Therapy 18.3.3. By Distribution Channel 18.4. Market Attractiveness Analysis 18.5. Drivers and Restraints - Impact Analysis 19. Key and Emerging Countries Market Analysis 2018 to 2023 and Forecast 2024 to 2034 19.1. Introduction 19.1.1. Market Value Proportion Analysis, By Key Countries 19.1.2. Global Vs. Country Growth Comparison 19.2. U.S. Market Analysis 19.2.1. By Therapy 19.2.2. By Distribution Channel 19.3. Canada Market Analysis 19.3.1. By Therapy 19.3.2. By Distribution Channel 19.4. Mexico Market Analysis 19.4.1. By Therapy 19.4.2. By Distribution Channel 19.5. Brazil Market Analysis 19.5.1. By Therapy 19.5.2. By Distribution Channel 19.6. U.K. Market Analysis 19.6.1. By Therapy 19.6.2. By Distribution Channel 19.7. Germany Market Analysis 19.7.1. By Therapy 19.7.2. By Distribution Channel 19.8. France Market Analysis 19.8.1. By Therapy 19.8.2. By Distribution Channel 19.9. Italy Market Analysis 19.9.1. By Therapy 19.9.2. By Distribution Channel 19.10. Spain Market Analysis 19.10.1. By Therapy 19.10.2. By Distribution Channel 19.11. BENELUX Market Analysis 19.11.1. By Therapy 19.11.2. By Distribution Channel 19.12. Russia Market Analysis 19.12.1. By Therapy 19.12.2. By Distribution Channel 19.13. China Market Analysis 19.13.1. By Therapy 19.13.2. By Distribution Channel 19.14. Japan Market Analysis 19.14.1. By Therapy 19.14.2. By Distribution Channel 19.15. South Korea Market Analysis 19.15.1. By Therapy 19.15.2. By Distribution Channel 19.16. India Market Analysis 19.16.1. By Therapy 19.16.2. By Distribution Channel 19.17. ASEAN Market Analysis 19.17.1. By Therapy 19.17.2. By Distribution Channel 19.18. Australia Market Analysis 19.18.1. By Therapy 19.18.2. By Distribution Channel 19.19. New Zealand Market Analysis 19.19.1. By Therapy 19.19.2. By Distribution Channel 19.20. GCC Countries Market Analysis 19.20.1. By Therapy 19.20.2. By Distribution Channel 19.21. Turkey Market Analysis 19.21.1. By Therapy 19.21.2. By Distribution Channel 19.22. South Africa Market Analysis 19.22.1. By Therapy 19.22.2. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Concentration 20.3. Market Share Analysis of Top Players 20.4. Market Presence Analysis 20.4.1. By Regional footprint of Players 20.4.2. Therapy foot print by Players 20.4.3. Channel Foot Print by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep dive 21.3.1. Boehringer Ingelheim GmbH 21.3.1.1. Overview 21.3.1.2. Therapy Portfolio 21.3.1.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.1.4. Sales Footprint 21.3.1.5. Strategy Overview 21.3.2. AbbVie 21.3.2.1. Overview 21.3.2.2. Therapy Portfolio 21.3.2.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.2.4. Sales Footprint 21.3.2.5. Strategy Overview 21.3.3. Regeneron Pharmaceuticals, Inc. 21.3.3.1. Overview 21.3.3.2. Therapy Portfolio 21.3.3.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.3.4. Sales Footprint 21.3.3.5. Strategy Overview 21.3.4. Novartis AG 21.3.4.1. Overview 21.3.4.2. Therapy Portfolio 21.3.4.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.4.4. Sales Footprint 21.3.4.5. Strategy Overview 21.3.5. Bristol-Myers Squibb Company 21.3.5.1. Overview 21.3.5.2. Therapy Portfolio 21.3.5.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.5.4. Sales Footprint 21.3.5.5. Strategy Overview 21.3.6. Pfizer Inc. 21.3.6.1. Overview 21.3.6.2. Therapy Portfolio 21.3.6.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.6.4. Sales Footprint 21.3.6.5. Strategy Overview 21.3.7. UCB S.A. 21.3.7.1. Overview 21.3.7.2. Therapy Portfolio 21.3.7.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.7.4. Sales Footprint 21.3.7.5. Strategy Overview 21.3.8. F. Hoffmann-La Roche Ltd. 21.3.8.1. Overview 21.3.8.2. Therapy Portfolio 21.3.8.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.8.4. Sales Footprint 21.3.8.5. Strategy Overview 21.3.9. Amgen, Inc. 21.3.9.1. Overview 21.3.9.2. Therapy Portfolio 21.3.9.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.9.4. Sales Footprint 21.3.9.5. Strategy Overview 21.3.10. Johnson & Johnson Services Inc. 21.3.10.1. Overview 21.3.10.2. Therapy Portfolio 21.3.10.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.10.4. Sales Footprint 21.3.10.5. Strategy Overview 21.3.11. Merck & Co. Inc. 21.3.11.1. Overview 21.3.11.2. Therapy Portfolio 21.3.11.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.11.4. Sales Footprint 21.3.11.5. Strategy Overview 21.3.12. Bristol-Myers Squibb Company 21.3.12.1. Overview 21.3.12.2. Therapy Portfolio 21.3.12.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.12.4. Sales Footprint 21.3.12.5. Strategy Overview 21.3.13. Eli Lilly and Company 21.3.13.1. Overview 21.3.13.2. Therapy Portfolio 21.3.13.3. Profitability by Market Segments (Therapy/Channel/Region) 21.3.13.4. Sales Footprint 21.3.13.5. Strategy Overview 22. Assumptions and Acronyms Used 23. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Volume (‘000 Units) Analysis and Opportunity Assessment 2018 to 2034, By Therapy
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Therapy
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Distribution Channel
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Region
Table 05: North America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 06: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Therapy
Table 07: North America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Distribution Channel
Table 08: Latin America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 09: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Therapy
Table 10: Latin America Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Distribution Channel
Table 11: Europe Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 12: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Therapy
Table 13: Europe Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Distribution Channel
Table 14: South Asia Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 15: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Therapy
Table 16: South Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Distribution Channel
Table 17: East Asia Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 18: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Therapy
Table 19: East Asia Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Distribution Channel
Table 20: Oceania Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 21: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Therapy
Table 22: Oceania Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Distribution Channel
Table 23: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 24: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Therapy
Table 25: Middle East and Africa Market Value (US$ Mn) Analysis and Opportunity Assessment 2018 to 2034, By Distribution Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Volume (in 000' Units) Analysis, 2018 to 2023
Figure 02: Global Market Volume Forecast (in 000' Units), 2024 to 2034
Figure 03: Pricing Analysis (US$) Per Therapy, By Region, 2023
Figure 04: Pricing Analysis (US$) Per Therapy, By Region, 2023
Figure 05: Global Market Value Analysis (US$ Mn), 2018 to 2023
Figure 06: Global Market Value Forecast (US$ Mn), 2024 to 2034
Figure 07: Global Market Absolute $ Opportunity, 2024 to 2034
Figure 08: Global Market Share Analysis (%), By Therapy, 2024 to 2034
Figure 09: Global Market Y-o-Y Analysis (%), By Therapy, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 11: Global Market Share Analysis (%), By Distribution Channel, 2024 to 2034
Figure 12: Global Market Y-o-Y Analysis (%), By Distribution Channel, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 14: Global Market Share Analysis (%), By Region, 2024 to 2034
Figure 15: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value Share, By Therapy, 2024 (E)
Figure 18: North America Market Value Share, By Distribution Channel, 2024 (E)
Figure 19: North America Market Value Share, By Country, 2024 (E)
Figure 20: North America Market Value Analysis (US$ Mn), 2018 to 2023
Figure 21: North America Market Value Forecast (US$ Mn), 2024 to 2034
Figure 22: North America Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 24: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 25: Latin America Market Value Share, By Therapy, 2024 (E)
Figure 26: Latin America Market Value Share, By Distribution Channel, 2024 (E)
Figure 27: Latin America Market Value Share, By Country, 2024 (E)
Figure 28: Latin America Market Value Analysis (US$ Mn), 2018 to 2023
Figure 29: Latin America Market Value Forecast (US$ Mn), 2024 to 2034
Figure 30: Latin America Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 31: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 32: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 33: Europe Market Value Share, By Therapy, 2024 (E)
Figure 34: Europe Market Value Share, By Distribution Channel, 2024 (E)
Figure 35: Europe Market Value Share, By Country, 2024 (E)
Figure 36: Europe Market Value Analysis (US$ Mn), 2018 to 2023
Figure 37: Europe Market Value Forecast (US$ Mn), 2024 to 2034
Figure 38: Europe Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 39: Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 40: Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 41: South Asia Market Value Share, By Therapy, 2024 (E)
Figure 42: South Asia Market Value Share, By Distribution Channel, 2024 (E)
Figure 43: South Asia Market Value Share, By Country, 2024 (E)
Figure 44: South Asia Market Value Analysis (US$ Mn), 2018 to 2023
Figure 45: South Asia Market Value Forecast (US$ Mn), 2024 to 2034
Figure 46: South Asia Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 47: South Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 48: South Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 49: East Asia Market Value Share, By Therapy, 2024 (E)
Figure 50: East Asia Market Value Share, By Distribution Channel, 2024 (E)
Figure 51: East Asia Market Value Share, By Country, 2024 (E)
Figure 52: East Asia Market Value Analysis (US$ Mn), 2018 to 2023
Figure 53: East Asia Market Value Forecast (US$ Mn), 2024 to 2034
Figure 54: East Asia Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 55: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 56: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 57: Oceania Market Value Share, By Therapy, 2024 (E)
Figure 58: Oceania Market Value Share, By Distribution Channel, 2024 (E)
Figure 59: Oceania Market Value Share, By Country, 2024 (E)
Figure 60: Oceania Market Value Analysis (US$ Mn), 2018 to 2023
Figure 61: Oceania Market Value Forecast (US$ Mn), 2024 to 2034
Figure 62: Oceania Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 63: Oceania Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 64: Oceania Market Attractiveness Analysis by Country, 2024 to 2034
Figure 65: Middle East and Africa Market Value Share, By Therapy, 2024 (E)
Figure 66: Middle East and Africa Market Value Share, By Distribution Channel, 2024 (E)
Figure 67: Middle East and Africa Market Value Share, By Country, 2024 (E)
Figure 68: Middle East and Africa Market Value Analysis (US$ Mn), 2018 to 2023
Figure 69: Middle East and Africa Market Value Forecast (US$ Mn), 2024 to 2034
Figure 70: Middle East and Africa Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 71: Middle East and Africa Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 72: Middle East and Africa Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: UNITED STATES Market Value Analysis (US$ Mn), 2024 & 2034
Figure 74: UNITED STATES Market Value Share, By Therapy, 2024 (E)
Figure 75: UNITED STATES Market Value Share, By Distribution Channel, 2024 (E)
Figure 76: Canada Market Value Analysis (US$ Mn), 2024 & 2034
Figure 77: Canada Market Value Share, By Therapy, 2024 (E)
Figure 78: Canada Market Value Share, By Distribution Channel, 2024 (E)
Figure 79: Mexico Market Value Analysis (US$ Mn), 2024 & 2034
Figure 80: Mexico Market Value Share, By Therapy, 2024 (E)
Figure 81: Mexico Market Value Share, By Distribution Channel, 2024 (E)
Figure 82: Brazil Market Value Analysis (US$ Mn), 2024 & 2034
Figure 83: Brazil Market Value Share, By Therapy, 2024 (E)
Figure 84: Brazil Market Value Share, By Distribution Channel, 2024 (E)
Figure 85: UNITED KINGDOM Market Value Analysis (US$ Mn), 2024 & 2034
Figure 86: UNITED KINGDOM Market Value Share, By Therapy, 2024 (E)
Figure 87: UNITED KINGDOM Market Value Share, By Distribution Channel, 2024 (E)
Figure 88: Germany Market Value Analysis (US$ Mn), 2024 & 2034
Figure 89: Germany Market Value Share, By Therapy, 2024 (E)
Figure 90: Germany Market Value Share, By Distribution Channel, 2024 (E)
Figure 91: France Market Value Analysis (US$ Mn), 2024 & 2034
Figure 92: France Market Value Share, By Therapy, 2024 (E)
Figure 93: France Market Value Share, By Distribution Channel, 2024 (E)
Figure 94: Italy Market Value Analysis (US$ Mn), 2024 & 2034
Figure 95: Italy Market Value Share, By Therapy, 2024 (E)
Figure 96: Italy Market Value Share, By Distribution Channel, 2024 (E)
Figure 97: Spain Market Value Analysis (US$ Mn), 2024 & 2034
Figure 98: Spain Market Value Share, By Therapy, 2024 (E)
Figure 99: Spain Market Value Share, By Distribution Channel, 2024 (E)
Figure 100: Russia Market Value Analysis (US$ Mn), 2024 & 2034
Figure 101: Russia Market Value Share, By Therapy, 2024 (E)
Figure 102: Russia Market Value Share, By Distribution Channel, 2024 (E)
Figure 103: China Market Value Analysis (US$ Mn), 2024 & 2034
Figure 104: China Market Value Share, By Therapy, 2024 (E)
Figure 105: China Market Value Share, By Distribution Channel, 2024 (E)
Figure 106: Japan Market Value Analysis (US$ Mn), 2024 & 2034
Figure 107: Japan Market Value Share, By Therapy, 2024 (E)
Figure 108: Japan Market Value Share, By Distribution Channel, 2024 (E)
Figure 109: South Korea Market Value Analysis (US$ Mn), 2024 & 2034
Figure 110: South Korea Market Value Share, By Therapy, 2024 (E)
Figure 111: South Korea Market Value Share, By Distribution Channel, 2024 (E)
Figure 112: India Market Value Analysis (US$ Mn), 2024 & 2034
Figure 113: India Market Value Share, By Therapy, 2024 (E)
Figure 114: India Market Value Share, By Distribution Channel, 2024 (E)
Figure 115: ASEAN Market Value Analysis (US$ Mn), 2024 & 2034
Figure 116: ASEAN Market Value Share, By Therapy, 2024 (E)
Figure 117: ASEAN Market Value Share, By Distribution Channel, 2024 (E)
Figure 118: Australia Market Value Analysis (US$ Mn), 2024 & 2034
Figure 119: Australia Market Value Share, By Therapy, 2024 (E)
Figure 120: Australia Market Value Share, By Distribution Channel, 2024 (E)
Figure 121: New Zealand Market Value Analysis (US$ Mn), 2024 & 2034
Figure 122: New Zealand Market Value Share, By Therapy, 2024 (E)
Figure 123: New Zealand Market Value Share, By Distribution Channel, 2024 (E)
Figure 124: GCC Countries Market Value Analysis (US$ Mn), 2024 & 2034
Figure 125: GCC Countries Market Value Share, By Therapy, 2024 (E)
Figure 126: GCC Countries Market Value Share, By Distribution Channel, 2024 (E)
Figure 127: Turkey Market Value Analysis (US$ Mn), 2024 & 2034
Figure 128: Turkey Market Value Share, By Therapy, 2024 (E)
Figure 129: Turkey Market Value Share, By Distribution Channel, 2024 (E)
Figure 130: South Africa Market Value Analysis (US$ Mn), 2024 & 2034
Figure 131: South Africa Market Value Share, By Therapy, 2024 (E)
Figure 132: South Africa Market Value Share, By Distribution Channel, 2024 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the market size for rheumatoid arthritis treatments in 2024?
The global market for rheumatoid arthritis treatment is estimated to reach US$ 35.84 billion in 2024.
Which country has a significant market share in rheumatoid arthritis treatment?
The United States is estimated to reach a market valuation of US$ 14.11 billion in 2024.
What is the market size of Latin America in 2024?
The Latin American market is estimated at US$ 1.6 billion in 2024.
Which distribution channel contributes to higher revenue from rheumatoid arthritis treatment?
Hospitals account for around 84.2% market share of the sales of rheumatoid arthritis drugs.
What is the market value of Brazil in 2024?
Brazil is projected to reach a market value of US$ 1.14 billion in 2024.
Rheumatoid Arthritis Treatment Market